^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

RAD51C expression

i
Other names: RAD51C, RAD51 paralog C, R51H3, BROVCA3, RAD51L2
Entrez ID:
Related biomarkers:
3ms
HBV promotes its replication by up-regulating RAD51C gene expression. (PubMed, Sci Rep)
Our results showed that RAD51C and HBV X protein(HBX) produced a direct interaction in the nucleus, the HBV infection of HCC cells promoted RAD51C expression, and the increased expression of RAD51C promoted HBV replication. This indicated that RAD51C is closely related to the occurrence and development of HCC caused by HBV infection, and may bring a breakthrough in the the prevention and treatment study of HCC.
Journal
|
RAD51C (RAD51 paralog C) • IFNA1 (Interferon Alpha 1)
|
RAD51C expression
over1year
Functional analysis of germline RAD51C missense variants highlight the role of RAD51C in replication fork protection. (PubMed, Hum Mol Genet)
In RAD51C deficient chinese hamster CL-V4B cells, expression of RAD51C F164S, A87E, L134S and E49K variants heightened sensitivity to mitomycin C (MMC), etoposide and PARP inhibition. Overall, our findings provide more insights into molecular roles of RAD51C in replication fork integrity maintenance and in DSB repair. Disclosure Summary The authors report no relevant conflicts of interest in this work.
Journal • PARP Biomarker
|
RAD51 (RAD51 Homolog A) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D)
|
RAD51C mutation • RAD51 mutation • RAD51C expression
|
etoposide IV • mitomycin
over1year
Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer. (PubMed, Clin Cancer Res)
In conclusion, a subset of colorectal cancers refractory to current therapies could benefit from inhibitors of DDR pathways and replication stress. A composite biomarker involving phospho-RPA32 and RAD51 foci, lack of ATM and RAD51C expression, as well as analysis of mutational signatures could be used to identify colorectal cancers likely to respond to ATRi.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • RAD51 (RAD51 Homolog A) • RAD51C (RAD51 paralog C) • CHEK1 (Checkpoint kinase 1) • RPA2 (Replication Protein A2)
|
KRAS mutation • BRAF mutation • ATM expression • RAD51 mutation • RAD51C expression
over2years
TAZ maintains telomere length in TNBC cells by mediating Rad51C expression. (PubMed, Breast Cancer Res)
This study supports the notion that TAZ is an oncogenic factor in TNBC, and further reveals a novel telomere-related pathway that is employed by TAZ to regulate TNBC.
Journal
|
TERT (Telomerase Reverse Transcriptase) • RAD51C (RAD51 paralog C)
|
RAD51C expression
almost3years
Characterization of a RAD51C-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance. (PubMed, NAR Cancer)
PH039 acquired PARPi resistance by the third treatment cycle and grew through subsequent treatment with either niraparib or rucaparib. Interestingly, the PARPi resistant PH039 model remained platinum sensitive. Collectively, these results not only indicate that PARPi treatment pressure can reverse RAD51C methylation and restore RAD51C expression, but also provide a model for studying the clinical observation that PARPi and platinum sensitivity are sometimes dissociated.
Preclinical • Journal • BRCA Biomarker • PARP Biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • RAD51C (RAD51 paralog C)
|
BRCA2 mutation • BRCA1 mutation • RAD51C mutation • RAD51 mutation • RAD51C expression
|
Zejula (niraparib) • Rubraca (rucaparib)